Press Release
Candel Therapeutics (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
–News Direct–
By Jeremy Golden, Benzinga
Immunotherapy has transformed the way cancer is treated, but just 20% to 40% of patients typically respond to FDA-approved immune checkpoint inhibitor (ICI) treatments.
Poor ICI treatment response has been linked to the tumors ability to disguise antigen presentation and generate an immunosuppressive microenvironment. In addition, most conventional immunotherapies are not designed to educate the patients immune system on how to recognize a variety of tumor antigens and neoantigens.
Amid this landscape, a clinical-stage biopharmaceutical company has developed a new multimodal biological approach that leverages the ability of viral gene constructs to activate cancer-killing mechanisms, exposing multiple tumor antigens to the immune system, resulting in vaccination against the tumor while inhibiting the immunosuppressive tumor microenvironment.
Candel Therapeutics, Inc. (NASDAQ: CADL) is developing a product candidate that is being studied in lung, pancreatic and prostate cancers. Candels most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf replication-defective adenovirus designed to induce an individualized, systemic immune response against the patients own tumor.
Part of the companys adenovirus platform, CAN-2409 is injected directly into the tumor or target tissue using a localized injection, akin to the standard approach for vaccination.
CAN-2409's adenoviral construct serves as a vector to transport the HSV-thymidine kinase gene into tumor cells at the site of injection. These tumor cells can then express HSV-thymidine kinase, which converts generic, FDA-approved anti-herpes drugs such as ganciclovir, acyclovir and valacyclovir into a toxic nucleotide analog that blocks DNA synthesis in dividing cells.
Cancer cells exposed to the toxic nucleotide analog in the tumor microenvironment have been observed to undergo immunogenic cell death. Simultaneously, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment, creating the optimal conditions to induce a specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad and systemic anti-tumor activity.
CAN-2409 is currently being studied in an open-label, phase 2 clinical trial in non-small cell lung cancer (NSCLC) and in randomized, controlled, blinded phase 2b and phase 3 clinical trials in prostate cancer. The company has recently released very encouraging data for CAN-2409s ability to improve overall survival in non-metastatic pancreatic cancer, with topline overall survival data in non-small cell lung cancer planned for this quarter (Q2 2024) and results from the prostate clinical trials later this year (Q4 2024).
When it comes to NSCLC, the company previously presented data from the phase 2 clinical trial in which patients received two administrations of CAN-2409 plus prodrug. Those patients demonstrated the following:
1) Increased infiltration of CD8+ cytotoxic T cells in the tumor microenvironment, systemic expansion of effector T cells and increased soluble granzyme B levels in peripheral blood;
2) Favorable changes in the trajectory of tumor progression;
3) Decreased tumor size of target lesions in most patients; and
4) Reduced size of uninjected tumor lesions.
The CAN-2409 immunotherapy antitumor strategy aims to increase the number of long survivors beyond 10 to 13 months.
As previous work has shown that progressive disease could be converted into stable disease in most patients with non-small cell lung cancer after CAN-2409 treatment, the hypothesis is that this will translate into improved survival.
When it comes to pancreatic cancer, the company reported notable improvements in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) after experimental treatment with CAN-2409. The estimated overall survival rate was 71.4% at 24 months in CAN-2409-treated patients versus only 16.7% in the control arm after chemoradiation.
In 2023, CAN-2409 received Fast Track Designation for both non-small cell lung cancer and pancreatic cancer, a validation from the FDA on its potential. CAN-2409 plus valacyclovir in combination with continued PD-1/PD-L1 agents is being evaluated in an ongoing, open-label phase 2 clinical trial in patients with late-stage NSCLC and an inadequate response to anti-PD(L)-1 therapy. In 2024, CAN-2409 also received Orphan Drug Designation from the FDA for CAN-2409 in borderline resectable pancreatic cancer.
In the upcoming year, Candel plans to announce data readouts for the following:
1) Phase 2 topline overall survival (OS) data for CAN-2409 in NSCLC, expected in Q2 2024;
2) Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer, expected in Q4 2024;
3) Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer, expected in Q4 2024.
Featured photo by National Cancer Institute on Unsplash.
Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candels enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
This article includes certain disclosures that contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Companys programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Companys ability to efficiently discover and develop product candidates; the Companys ability to obtain and maintain regulatory approval of product candidates; the Companys ability to maintain its intellectual property; the implementation of the Companys business model, and strategic plans for the Companys business and product candidates, and other risks identified in the Companys SEC filings, including the Companys most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
Contact Details
Aljanae Reynolds
+1 617-916-5445
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/candel-therapeutics-nasdaq-cadl-lead-candidate-can-2409-combats-lung-pancreatic-and-prostate-cancers-with-fast-track-designation-for-three-cancers-458506267
Candel Therapeutics
COMTEX_453480918/2655/2024-06-07T08:28:02
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
DemanPlay Surpasses 200,000 Discord Community Members, Expanding Its Chinese Gaming Community Ecosystem in NA
United States, 19th Mar 2026DemanPlay, a Chinese gaming community in NA, announced that as of March 15, 2026, the total number of members across its Discord communities has officially surpassed 200,000, marking a major milestone in its long-term growth.
According to the platform’s latest internal data, approximately 30% of its community users are located in Canada and 62% are based in the United States, based on IP address distribution across its online community. The remaining users mainly come from regions including Europe and Australia. The platform continues to grow steadily, adding around 3,500 new users per month and attracting Chinese-speaking gamers from across Canada and the U.S.
As its community continues to expand, DemanPlay has further strengthened its presence in gaming social networking, team matchmaking, interactive companionship services, and diversified online entertainment. Since its founding in 2018, DemanPlay has operated steadily for eight years, gradually building a mature and scalable community ecosystem.
One of DemanPlay’s core strengths is its response efficiency. Based on internal platform data, the average response time from a user placing an order to someone accepting it is under five seconds across all supported game categories. This reflects the platform’s continued advantage in both activity level and matchmaking speed.
In addition to fast response and matchmaking, DemanPlay has established a unified recharge and account system that allows users to recharge once and use their balance across multiple services within the community. These services include, but are not limited to, account rentals, in-game item trading, and other interactive gaming-related services. The platform also operates an automated after-sales system and 24/7 customer support, providing users with a stable and efficient service experience.
At present, DemanPlay’s main community covers multiple popular game sections, including:
- League of Legends
- VALORANT
- CS2
- PUBG
In addition, the platform also operates a dedicated Delta Force international server community, further meeting the social and matchmaking needs of different player groups.
Beyond gaming itself, DemanPlay continues to expand its community content ecosystem with a range of lifestyle and interest-based sections, including player selfie sharing, job information exchange, astrology discussions, and car and model collecting. These features help users build more authentic and engaging connections outside of gaming.
In terms of service coverage, DemanPlay currently supports multiple popular titles and interactive entertainment categories, including but not limited to:
- League of Legends (NA)
- VALORANT (NA)
- CS2 (NA)
- Delta Force (CN and International)
- Teamfight Tactics (NA)
- Overwatch 2 (NA)
- APEX Legends (NA)
The platform also offers entertainment-based interactive services such as music request sessions, Werewolf-style social games, and Goose Goose Duck, creating a more diversified online entertainment experience for users.
Beyond community operations and service infrastructure, DemanPlay’s North American team Deman Esport has also delivered strong competitive results. In 2024, Deman Esport won the championship in the North America Grand Final of the Naraka: Bladepoint Koi Cup, demonstrating the competitive strength of both its player community and team structure.
Ria Li said that reaching 200,000 users is not only a milestone for the community, but also a reflection of the growing demand among Chinese gamers in North America for high-quality online gaming communities and interactive services.
Daniel Hu said the platform will continue to improve its technical capabilities and user service systems while expanding into more game categories and community interaction scenarios.
Aaron Wan said DemanPlay will continue to strengthen its brand presence and community-building capabilities, with the goal of creating a more welcoming, active, and engaging environment for Chinese gamers across North America.
As one of the important Chinese online gaming communities in North America, DemanPlay will continue to invest in community experience, service efficiency, and content expansion, providing a richer, faster, and more interactive entertainment environment for gamers across the region.
Media Contact
Organization: Demanplay
Contact Person: Aaron Wan
Website: http://demanplay.com/
Email: Send Email
Country:United States
Release id:42736
The post DemanPlay Surpasses 200,000 Discord Community Members, Expanding Its Chinese Gaming Community Ecosystem in NA appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Pioneering Psychedelic Harm Reduction: Mushrooms.support Bridges the Gap Between Colorado’s Legal Reforms and Evidence-Based Psilocybin and DMT Education
DENVER, COLORADO – March 18, 2026 – As Colorado continues to lead the nation in progressive psychedelic legislation under the Natural Medicine Health Act (NMHA), a groundbreaking Denver-based platform is setting the global standard for safety, education, and integration. Mushrooms.support, operating under Lyman Support Centers LLC, has officially announced the expansion of its comprehensive ecosystem dedicated to harm reduction, non-commercial gifting, and guided support for adults exploring the therapeutic benefits of psilocybin and dimethyltryptamine (DMT).
Following the historic voter approval of Proposition 122 and subsequent SB23-290 refinements, Colorado decriminalized the personal use, possession, and sharing of natural medicines for adults over 21. Navigating this new legal landscape, Mushrooms.support emerges as a vital community hub. Operating strictly within the non-commercial parameters of the law, the platform facilitates the free gifting of psilocybin and DMT while offering paid, professionally guided harm reduction sessions ranging from an accessible $10 to $200. This model ensures that life-changing mental health support and safety are accessible to all demographics, effectively removing the financial barriers often associated with psychedelic-assisted care.
The Scientific Foundation of Therapeutic Psychedelics The platform’s mission is deeply rooted in cutting-edge clinical research. Recent phase III trials and landmark studies from institutions like Johns Hopkins University have demonstrated the profound efficacy of psilocybin in treating Major Depressive Disorder (MDD), Treatment-Resistant Depression (TRD), and end-of-life existential anxiety.
By acting as a serotonin 5-HT2A receptor agonist, psilocybin promotes neuroplasticity, helping to rewire maladaptive thought patterns. Similarly, emerging research highlights endogenous DMT’s potential as a rapid-acting antidepressant and neuroprotectant. Mushrooms.support translates this complex science into actionable guidance for individuals dealing with PTSD, OCD, cluster headaches, and substance use disorders.
Award-Winning Harm Reduction Principles Recognized as the “Psychedelic Cup 2025 Winner” and awarded “Most Homogeneous” for its consistent quality and safety standards, Mushrooms.support distinguishes itself through five core principles of harm reduction:
1. Rigorous Testing: Ensuring the purity and safety of natural medicines.
2. Comprehensive Education: Providing transparent data on physiological effects and risks.
3. Set and Setting Preparation: Guiding users to create optimal environments for psychological safety.
4. On-Site Guided Support: Offering trained presence during the experience.
5. Post-Experience Integration: Helping users process and apply their insights for long-term personal growth.
Trained ambassadors and medical referrals are available to ensure that every individual’s journey is safe and therapeutically beneficial. The platform also strictly educates on contraindications, prominently warning against the risks of serotonin syndrome for individuals on specific medications or those with underlying cardiovascular or psychotic conditions.
“Decriminalization is only the first step; the true evolution of mental health care requires a solid foundation of safety, education, and community support,” says Darren Lyman, founder of Mushrooms.support and author of foundational texts on psychedelic integration. “Our goal is to transform Colorado’s legal framework into a scientifically grounded, accessible public health strategy. We are providing the essential resources—from microdosing guides to post-session integration—so individuals can explore these powerful natural medicines without fear or stigma.”
A Comprehensive Community Ecosystem Beyond one-on-one support, the Denver facility (located at 800 W. 8th Ave #110) and its digital platform offer an expansive library of resources. Users can access microdosing protocols, integration workbooks, specialized PDF drink recipes, chocolate formulations, and connections to trusted community growers and wellness products like Epic Balms.
As the psychedelic renaissance accelerates in 2026, Mushrooms.support stands at the forefront of the movement, ensuring that the integration of psilocybin and DMT into mainstream wellness is conducted ethically, safely, and equitably.
For more information, to access harm reduction resources, or to schedule a session, visit Website.
About Mushrooms.support
Mushrooms.support is a Denver-based educational and harm reduction platform operating under the Colorado Natural Medicine Health Act. Founded by Darren Lyman and managed by Lyman Support Centers LLC, the center provides non-commercial gifting of natural medicines alongside expert-guided support, integration services, and scientific resources for adults 21 and older. Operations run Tuesday through Saturday from 2:00 PM to 6:45 PM.
Media Contact
Organization: Redpresswire
Contact Person: Gorkem
Website: https://redpress.net
Email: Send Email
Contact Number: +905451552424
Address:Suite 10560 5 Brayford Square
City: London
Country:United Kingdom
Release id:42791
Disclaimer: This press release is for informational purposes only. Statements regarding therapeutic effects of psilocybin and DMT are based on research and do not constitute medical advice. Individuals should consult qualified healthcare professionals before using these substances.
The post Pioneering Psychedelic Harm Reduction: Mushrooms.support Bridges the Gap Between Colorado’s Legal Reforms and Evidence-Based Psilocybin and DMT Education appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
BiFinance, a leading Web3 digital asset trading platform, has officially announced the listing of EVOCARE (EVOCARE) and the launch of a dedicated trading competition, offering users multiple participation opportunities and enhanced engagement.
EVOCARE Officially Listed on BiFinance
According to the official announcement, BiFinance has listed the EVOCARE USDT trading pair, with deposit and trading services opened on March 12, 2026.
EVOCARE represents an innovative Web3 healthcare initiative focused on building a digital therapy ecosystem. As The World Therapy Store, EvoCare aims to connect patients, therapists, and healthcare creators through a scalable and compliant infrastructure, integrating real-world medical services with blockchain technology and bringing real-world utility into the Web3 space.
The platform combines regulated healthcare services with Web3 utility infrastructure, creating a scalable global ecosystem for therapy, rehabilitation, and digital health services. EvoCare is designed to enable German-quality therapeutic care to be delivered anywhere in the world through a clinically supervised digital healthcare platform.
Official Website:
https://evocare.healthcare
The EVOCARE token serves as the core of the ecosystem, supporting:
Digital therapy service payments
Creator support mechanisms
Access to regulated healthcare solutions
By linking real healthcare demand with tokenized utility, EVOCARE creates a sustainable and value-driven ecosystem backed by real-world applications.
Trading Competition Now Live with Trading Competition Details
To celebrate the listing, BiFinance has launched the EVOCARE Trading Competition, allowing users to trade EVOCARE USDT and compete for benefits.
Participants can:
Trade EVOCARE USDT to climb leaderboard rankings
Receive benefits based on trading performance
Unlock additional advantages such as trading additional benefits
The competition is designed to encourage active participation while benefiting both new and experienced traders.
Expanding the RWA and Utility-Driven Ecosystem
The listing of EVOCARE reflects BiFinance’s continued commitment to supporting projects with real-world utility and strong growth potential. By bridging traditional sectors such as healthcare with blockchain infrastructure, BiFinance further strengthens its “virtual + real” ecosystem strategy.
Through ongoing listings, trading campaigns, and ecosystem collaboration, BiFinance aims to provide users with:
High-quality asset access
Enhanced trading opportunities
A more diversified and utility-driven Web3 experience
About BiFinance
BiFinance is a Web3 digital asset trading platform focused on the integration of Real-World Assets (RWA) and blockchain technology. The platform is committed to building a secure, compliant, and scalable financial ecosystem, connecting traditional finance with the decentralized world.
With a growing global presence and continuous innovation in both product and ecosystem design, BiFinance is accelerating the evolution of digital finance through its “Bi+Finance” model.
Media Contact
Organization: BiFinance
Contact Person: Ben
Website: https://www.bifinance.com
Email:
listing@BiFinance.com
Country:Canada
Release id:42777
The post BiFinance Lists EVOCARE-USDT and Launches Trading Competition with Exclusive Rewards appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
DemanPlay Surpasses 200,000 Discord Community Members, Expanding Its Chinese Gaming Community Ecosystem in NA
Pioneering Psychedelic Harm Reduction: Mushrooms.support Bridges the Gap Between Colorado’s Legal Reforms and Evidence-Based Psilocybin and DMT Education
BiFinance Lists EVOCARE-USDT and Launches Trading Competition with Exclusive Rewards
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release1 week ago
Post Oak Group Expands Its Capital Markets Practice Into European Markets
-
Press Release6 days ago
ForexBrokers.Live: Simplifying MT4 and MT5 for Forex Traders
-
Press Release7 days ago
Brian Hagerty Brings Proven Service Industry Leadership and Operational Expertise to Next Chapter
-
Press Release5 days ago
European Scientologists Expand Human Rights Education in Europe and Abroad
-
Press Release7 days ago
A Mathematician’s Perspective: The MatrixFlow Model Behind Feather Exchange
-
Press Release7 days ago
Somos Martina Launches Period Uniform Program, Integrating Period Underwear into Colombian School Uniform System
-
Press Release1 week ago
Yijin Solution Optimizes Multi-Axis Manufacturing with Next-Generation 5-Axis CNC Machining
-
Press Release5 days ago
Ernie Williams’ “Wired for Disaster” Hits no.1 on Amazon, Offering a Practical Guide to Surviving and Rebuilding After an EMP Event